This decision did not emerge from the Advisory Committee on Immunization Practices (ACIP), which typically guides the CDC’s ...

WHO Member States have concluded the latest round of negotiations on the world’s first Pathogen Access and Benefit-Sharing (PABS) system, agreeing to resume discussions in January as countries push ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

A new variant of the FileFix social engineering attack uses cache smuggling to secretly download a malicious ZIP archive onto a victim’s system and bypassing security software. The new phishing and ...

FDA approval enables Complement Therapeutics to start the Opti-GAIN phase 1/2 trial for CTx001 in GA secondary to AMD. CTx001 is an AAV-based gene therapy delivering a truncated Complement Receptor 1 ...

The electric vehicle revolution is here. For businesses, commercial properties, and apartment buildings, installing EV charging stations is no longer a luxury—it’s a necessity to attract tenants, ...

Aptamer Group plc, a developer of next-generation synthetic binders for the life sciences industry, has signed a new therapeutic development agreement with Invizius, a clinical-stage biotechnology ...

Using animal models, researchers uncovered how cervical and throat cancers linked to the human papillomavirus evade the immune system, opening the door to new treatment. The most common cancer-causing ...